Satellos Bioscience Inc. MSLE
Annual
Quarterly
No annual revenue total was found in Satellos Bioscience Inc.'s SEC filings.
Satellos Bioscience Inc. (MSLE) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$23.6 million.
Revenue
—
Net income
$-24.87M
Operating cash flow
$-23.60M
Free cash flow
$-23.60M
EPS
$-1.70
Dividend per share
None
Shares outstanding
15.46M
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MSLE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Canada (Federal Level)
- Headquarters
- Markham
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1421642
- Former names
- ICO THERAPEUTICS INC (until Sep 10, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
|---|---|
| Operating income | -$26.5M |
| Net income | -$24.9M |
| Diluted EPS | -$1.70 |
| Operating cash flow | -$23.6M |
| Free cash flow | -$23.6M |
| Total assets | $31.9M |
| Total liabilities | $4.1M |
| Stockholders' equity | $27.8M |
| Cash and investments | $9.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 27, 2026 | Oct 27, 2026 |
| 6-K | Current report (foreign issuer) | Oct 21, 2026 | Oct 21, 2026 |
| 6-K | Current report (foreign issuer) | Oct 5, 2026 | Oct 5, 2026 |
| 6-K | Current report (foreign issuer) | Sep 30, 2026 | Sep 30, 2026 |
| 6-K | Current report (foreign issuer) | Sep 24, 2026 | Sep 24, 2026 |
| 6-K | Current report (foreign issuer) | Sep 15, 2026 | Sep 15, 2026 |
All 53 Satellos Bioscience Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.